Global pharmaceutical company Lupin Limited has announced the launch of Ajaduo M Forte, a novel triple fixed-dose combination (FDC) therapy for the management of Type 2 Diabetes Mellitus (T2DM) in India. Ajaduo M Forte combines three well-established agents- Empagliflozin, Linagliptin, and Metformin Extended Release (ER)- into a single daily tablet, simplifying treatment regimens for patients struggling with diabetes and its associated complications. The product will be available in two strengths: Ajaduo M Forte 25: Empagliflozin 25 mg + Linagliptin 5 mg + Metformin ER 1000 mg at 21 Rs/ TabAjaduo M Forte 10: Empagliflozin 10 mg + Linagliptin 5 mg + Metformin ER 1000 mg at 19 Rs/Tab Empagliflozin, an SGLT2 inhibitor, promotes urinary glucose excretion and offers cardiovascular and renal benefits. Linagliptin, a DPP-4 inhibitor, enhances incretin levels to improve insulin secretion and reduce glucagon release. Metformin ER improves insulin sensitivity and suppresses hepatic glucose production. With its focused Fixed dose combinations, Ajaduo M Forte specifically targets multiple pathophysiological defects described in the Ominous Octet model, addressing key contributors such as insulin resistance, beta-cell dysfunction, and increased renal glucose reabsorption. It is the only USFDA-approved fixed-dose triple combination of Empagliflozin, Linagliptin, and Metformin, providing a comprehensive approach to glycemic control. The formulation aligns with globally recognized guidelines, including those issued by the ADA/EASD and RSSDI, reinforcing its clinical relevance and utility in modern diabetes management. Commenting on the launch, Mr Gagan Arora, Vice President Sales and Marketing, “Ajaduo M Forte reflects our commitment to delivering innovative, patient-centric solutions. This triple combination simplifies therapy while offering robust efficacy aligned with international recommendations, enabling better long-term outcomes for diabetes patients in India.” With Empagliflozin going off-patent, Lupin has strategically expanded its diabetes portfolio by launching Ajaduo, a fixed-dose combination (FDC) of Empagliflozin and Linagliptin, available in Ajaduo 10/5 and Ajaduo 25/5. Additionally, the company has introduced Ajaduo M Forte, a triple FDC of Empagliflozin, Linagliptin, and Metformin Extended Release, available in Ajaduo M Forte 25 and Ajaduo M Forte 10. You can read about it at the link below: https://medicaldialogues.in/md-brand-connect/lupin-launches-empagliflozin-linagliptin-fdc-ajaduo-at-affordable-prices-144755